ThinkSabio

$CORT

$72.70▲ -0.3% YTD

11 SEC 13D/G filings tracked · Last updated Nov 16, 2026

Filing History
News
CORT ▼ -0.3% - Corcept Therapeutics Incorporated
CP $72.70▲ -0.3%Nov 16, 2026 · ThinkSabio Blog

$CORT - ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer…

News
CORT ▼ -2.9% - Corcept Therapeutics Incorporated
CP $79.50▲ -2.9%Nov 4, 2026 · ThinkSabio Blog

$CORT Piper Sandler analyst David Amsellem raised the firm's price target on Corcept Therapeutics to $173 from $165 and keeps an Overweight rating on…

News
CORT ▼ -3.6% - Corcept Therapeutics Incorporated
CP $77.58▲ -3.6%Nov 3, 2026 · ThinkSabio Blog

$CORT reported Q3 2026 EPS of $1.01, beating the $0.81 estimate by 24.7%. Revenue of $340.5M beat the $334.9M estimate by 1.7%…

News
CORT ▼ -6.3% - Corcept Therapeutics Incorporated
CP $75.40▲ -6.3%Nov 3, 2026 · ThinkSabio Blog

$CORT - Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update…

SEC 13D/G
CORT - Corcept Therapeutics Incorporated - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks Simplified
$87.59▲ 129.41%Oct 27, 2026 · ThinkSabio Blog

$CORT SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #CORT Corcept Therapeutics Incorporated : $87.59 Sector: Healthc…

News
CORT ▼ -1.0% - Corcept Therapeutics Incorporated
CP $85.05▲ -1.0%Oct 26, 2026 · ThinkSabio Blog

$CORT - Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-…

News
CORT ▼ -1.0% - Corcept Therapeutics Incorporated
CP $85.05▲ -1.0%Oct 26, 2026 · ThinkSabio Blog

$CORT Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Re…

News
CORT ▼ -13.2% - Corcept Therapeutics Incorporated
CP $93.26▲ -13.2%Oct 23, 2026 · ThinkSabio Blog

$CORT vol lows following GMAB headlines…

News
CORT ▲ +3.9% - Corcept Therapeutics Incorporated
CP $116.45▲ +3.9%Oct 20, 2026 · ThinkSabio Blog

$CORT - 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes…

News
CORT ▲ +0.0% - Corcept Therapeutics Incorporated
CP $117.50▲ +0.0%Sep 23, 2026 · ThinkSabio Blog

$CORT - Corcept Announces Planned Leadership Transition…

News
CORT ▼ -0.1% - Corcept Therapeutics Incorporated
CP $114.86▲ -0.1%Sep 18, 2026 · ThinkSabio Blog

$CORT - Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)…